«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

23卷

期数:

2017年06期

页码:

519-522

栏目:

临床医学

出版日期:

2017-11-20

文章信息/Info

Title:

Expression and significance of serum microRNA-183 in hepatocellular carcinoma

作者:

张自立¹; 2; 3; 石文霞³; 李 霖²; 孟祥朝²; 高英堂³; 杜 智³

(1.天津医科大学三中心临床学院普通外科,天津300170;2.天津市第三中心医院普通外科,天津300170；3.天津市肝胆疾病研究所，天津市人工细胞重点实验室，卫生部人工细胞工程技术研究中心，天津 300170)

Author(s):

ZHANG Zi-li¹; 2; 3; ?SHI Wen-xia³; LI Lin²; MENG Xiang-chao²; GAO Ying-tang³;  DU Zhi³

 

（1.Department of General Surgery，The Third Central Clinical College ,Tianjin Medical University, Tianjin 300170, China; 2. Department of General Surgery， Tianjin Third Central Hospital, Tianjin 300170, China;3.Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin 300170, China）

关键词:

微小RNAs; 肝细胞癌; 血清; miR-183

Keywords:

microRNAs;  hepatocellular carcinoma; serum; miR-183

分类号:

R735.7

DOI:

-

文献标志码:

-

摘要:

目的：比较肝癌及良性肝病患者血清中miRNA-183的表达并探讨其临床意义。方法：收集肝癌患者血清标本54例，肝硬化患者血清标本45例，肝炎患者血清标本30例及健康体检者血清标本45例，荧光定量PCR检测miRNA-183在各组中的表达量及分析肝癌组与临床病理特征之间的关系。结果：肝癌患者血清中miR-183表达量高于正常对照组，也高于肝炎组及肝硬化组（P <0.05）；肝硬化组血清miR-183表达量高于正常对照组（P <0.05）。肝癌患者的血清miR-183表达量与TNM分期有关，Ⅲ～Ⅳ期的表达水平高于Ⅰ～Ⅱ期（P <0.05）；低分化肝癌患者血清miR-183的表达水平高于高-中分化患者（P <0.05）；伴有肝硬化的肝癌患者其血清miR-183表达水平高于不伴肝硬化者（P <0.05）。ROC曲线下面积为0.699（95% CI 0.613～0.784），最佳临界值为1.38，相应的敏感性为53.7%,特异性为83.3%,阳性预测值为60.1%,阴性预测值为76.9%。结论：血清miR-183可能作为诊断肝癌的新型肿瘤标志物，并可能预测肝癌预后。

Abstract:

Objective: To compare the expression of miR-183 in hepatocellular carcinoma(HCC) serum and benign liver diseases and explore its clinical significance. Methods: Serum miR-183 expression was measured in HCC serum(n =54), liver cirrhosis (LC) serum(n =45),chronic viral hepatitis (CH) serum(n =30) and normal controls (NC) (n =45)by quantitative real-time reverse-transcription polymerase chain reaction(qRT-PCR). Results: The expression of serum miR-183 in HCC was higher than those in normal controls, hepatitis and cirrhosis patients(P <0.05); the expression of serum miR-183 in cirrhosis patients was also higher than that in normal controls(P <0.05). The expression of serum miR-183 was higher in Ⅲ～Ⅳ stage than that in Ⅰ～Ⅱ stage in HCC(P <0.05); well-differentiated HCC was lower than that in poor-differentiated HCC (P<0.05); and HCC patients with cirrhosis had a higher expression of miR-183 than those without cirrhosis. ROC curve of serum miR-183 in HCC had an ideal diagnostic value, with a optimal value of 1.38; the diagnostic sensitivity and specificity were 53.7% and 83.3%, respectively and the positive predictive value and negative predictive value were 60.1%, 76.9%， respectively. Conclusion: Serum miR-183 may act as a new tumor marker and may predict the prognosis and therapeutic effect.

参考文献/References:

[1]Zhu R X, Seto W K, Lai C L, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J]. Gut Liver,2016,10(3):332
[2]左婷婷,郑荣寿,曾红梅,等.中国肝癌发病状况与趋势分析[J].中华肿瘤杂志,20159):691
[3]Fukuda S, Itamoto T, Nakahara H, et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma[J]. Hepatogastroenterol, 2005,52 (64):1163
[4]Yuen M F, Cheng C C, Lauder I J, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience[J].Hepatol,2000,31(2):330
[5]Pillai R S, Bhattacharyya S N, Artus C G, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells[J].Sci,2005,309(5740):1573
[6]Barshack I, Meiri E, Rosenwald S, et al. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression[J].Int J Biochem Cell Biol,2010,42(8):1355
[7]Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer[J].J Cancer Res Clin Oncol,2013,139(2):223
[8]Gilad S, Meiri E, Yogev Y, et al. Serum MicroRNAs are promising novel biomarkers[J].PLoS One,2008,3(9):e3148
[9]Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J].J Hepatol, 2012,56(1):167
[10]Xu J, Li J, Zheng T H, et al. MicroRNAs in the occurrence and development of primary hepatocellular carcinoma[J].Adv Clin Exp Med,2016,25(5):971
[11]Li J, Shi W, Gao Y, et al. Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma[J].Clin Lab,2013,59(9/10):1009
[12]Jiang L, Cheng Q, Zhang B H, et al. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China[J].Med,2015,94(10):e603
[13]Myatt S S, Wang J, Monteiro L J, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer[J].Cancer Res,2010,70(1):367
[14]Chen L, Li Y, Fu Y, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue[J].PLoS One,2013,8(1):e54213
[15]Zhu J, Feng Y, Ke Z, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin[J].Am J Pathol,2012,180(6):2440
[16]Liang Z, Gao Y, Shi W, et al. Expression and significance of microRNA-183 in hepatocellular carcinoma[J]. Sci World J, 2013:381874
[17]Zhang Y, Li T, Qiu Y, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma[J].Med,2017,96(2):e5642
[18]贺小停,曹秀峰.miRNA与食管癌[J].世界华人消化杂志,2007,15(19):2133

相似文献/References:

[1]周冷潇,韩 涛.慢性乙型病毒性肝炎肝硬化发生肝细胞癌的危险因素分析[J].天津医科大学学报,2017,23(03):214.
　ZHOU Leng-xiao,HAN Tao.Risk factors of hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J].Journal of Tianjin Medical University,2017,23(06):214.
[2]周冷潇,韩 涛,刘 芳.无创肝纤维化指标结合甲胎蛋白对乙型肝炎相关肝细胞癌的评估[J].天津医科大学学报,2017,23(05):415.
　ZHOU Leng-xiao,HAN Tao,LIU Fang.Assessment of non-invasive fibrosis indexes with alpha-fetoprotein?for? hepatitis B virus-related hepatocellular carcinoma[J].Journal of Tianjin Medical University,2017,23(06):415.
[3]侯振宇,孔银龙,孙 林,等.92例晚期肝细胞癌患者肝切除预后及危险因素分析[J].天津医科大学学报,2018,24(05):425.
　HOU Zhen-yu,KONG Yin-long,SUN Lin,et al.Prognosis and survival risk factors for 92 advanced hepatocellular carcinoma patients after hepatectomy[J].Journal of Tianjin Medical University,2018,24(06):425.
[4]胡 源,许戈良,荚卫东,等.C1QL1蛋白在原发性肝细胞癌中的表达及其临床意义[J].天津医科大学学报,2019,25(04):329.
　HU Yuan,XU Ge-liang,JIA Wei-dong,et al.Expressions of C1QL1 protein inprimaryhepatocellular carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2019,25(06):329.
[5]李亚冲,刘颖,朱恩东.miR-20a-5p调控成骨细胞分化相关靶基因的筛选及靶向关系验证[J].天津医科大学学报,2020,26(03):204.
　LI Ya-chong,LIU Ying,ZHU En-dong.Screening of the target gene and verification of its targeting relationship with miR-20a-5p to regulate osteoblast differentiation[J].Journal of Tianjin Medical University,2020,26(06):204.
[6]张萃萃,邓为民.基因表达谱分析肝细胞癌的特征基因[J].天津医科大学学报,2020,26(06):514.
　ZHANG Cui-cui,DENG Wei-min.Gene expression profiling reveals important characteristic genes in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2020,26(06):514.
[7]张杨,游阿彬,齐寒,等.负载化疗药物的外泌体对肝癌的靶向治疗研究[J].天津医科大学学报,2021,27(03):229.
　ZHANG Yang,YOU A-bin,QI Han,et al.Tumor-derived exosomes mediate targeted therapy in hepatocellular carcinoma mice[J].Journal of Tianjin Medical University,2021,27(06):229.
[8]王凤松,朱刘洋,白易,等.基于肿瘤突变负荷构建肝细胞癌风险评分预后模型[J].天津医科大学学报,2022,28(01):20.
　WANG Feng-song,ZHU Liu-yang,BAI Yi,et al.Identification of a risk score prognostic model of hepatocellular carcinoma based on tumor mutation burden[J].Journal of Tianjin Medical University,2022,28(06):20.
[9]赵耕,张盈莹,卓永,等.藏区慢性乙型肝炎患者使用PAGE-B模型对肝细胞癌的风险预测研究[J].天津医科大学学报,2022,28(06):654.
　ZHAO Geng,ZHANG Ying-ying,ZHUO Yong,et al.Risk prediction of hepatocellular carcinoma using the PAGE-B model in Tibetan patients with chronic hepatitis B[J].Journal of Tianjin Medical University,2022,28(06):654.
[10]张华,范松,刘冀琴,等.miR-129-5p通过靶向SALL4抑制肝癌细胞增殖、迁移和侵袭的实验研究[J].天津医科大学学报,2024,30(01):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]
　ZHANG Hua,FAN Song,LIU Jiqin,et al.The experimental study of miR-129-5p inhibiting proliferation， migration， and invasion of hepatocellular carcinoma by targeting to SALL4[J].Journal of Tianjin Medical University,2024,30(06):11.[doi:10.20135/j.issn.1006-8147.2024.01.0011]

备注/Memo

备注/Memo:

作者简介 张自立（1980-）， 男，硕士在读，研究方向：普通外科；通信作者：杜智，E-mail:zhi-du@163.com。

常用功能

更新日期/Last Update: 2017-11-14